Opportunities in meniscus replacement and cartilage repair have long been under-realized in orthopedics--victims of both strong markets for core products, most notably total knee replacements, and the challenges of developing devices that work well. Now two start-ups, sister companies launched by UK-based serial entrepreneurs Oakes, Lyman, believe they've found the technology to tap these opportunities.
David Cassak
So robust has the total knee replacement opportunity been for Big Ortho over the past 30 years that it’s sometimes...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
